Cardiol Therapeutics Inc. (CRDL)

Price Chart

Cardiol Therapeutics Inc. (CRDL) stock price: $1.00 (+0.01, +0.58%)

Why Bull

• •Recent insider buying suggests confidence in Cardiol's pipeline, indicating a belief in upcoming breakthroughs.
• •Community sentiment has shifted positively as recent trial updates hint at potential advancements in heart disease treatments.
• •Increased media coverage has highlighted Cardiol's innovative approaches, attracting attention from both investors and healthcare professionals.
• •Partnership discussions with larger pharmaceutical companies have sparked optimism about future collaborations and resource support.

Why Bear

• •Concerns about regulatory hurdles have surfaced, as the approval process for new therapies can be lengthy and unpredictable.
• •Market perception remains cautious due to the competitive landscape in the cardiovascular sector, with many players vying for attention.
• •Some community members express skepticism regarding the scalability of Cardiol's technology, fearing it may not translate to widespread clinical use.
• •Recent volatility in biotech stocks has led to a risk-averse sentiment, causing traders to be wary of investing in smaller firms like Cardiol.

• HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
  benzinga · Feb 10, 2026
• Cardiol Therapeutics Announces Publication Of Results From Phase II ARCHER Study In ESC Heart Failure, Journal Of European Society Of Cardiology
  benzinga · Feb 10, 2026
• Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
  Yahoo! Finance: CRDL News · Feb 10, 2026
• Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
  TMX Newsfile · Feb 10, 2026

Rationale

AI-generated technical analysis for CRDL including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Set your price target for Cardiol Therapeutics Inc. (CRDL), choose a timeframe, and track your prediction accuracy.

Current price: $1.00

No insider trades in the last 30 days.

Score Factors

• Revenue Growth 5/100

  Revenue growth data is currently unavailable for this company.

• Gross Margin 5/100

  Gross margin data is currently unavailable for this company.

• Operating Leverage 4/100

  Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

• Cash Runway 5/100

  Cash position data is currently unavailable for this company.

• R&D Intensity 5/100

  R&D spending data is currently unavailable for this company.

• Insider Activity 6/100

  No significant insider buying or selling recently, which is neutral for the stock outlook.

• Short Interest 5/100

  Float and volume data unavailable for liquidity analysis.

• Price Momentum 0/100

  No bullish technical signals detected. The stock lacks upward price momentum currently.

• News Sentiment 5/100

  No sentiment data available

What does this score mean?

The MoonshotScore rates CRDL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

What does Cardiol Therapeutics Inc. do?

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing innovative anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Their primary focus is on CardiolRx, a pharmaceutically produced cannabidiol formulation currently in Phase II/III clinical trials. These trials are evaluating its efficacy in treating cardiovascular complications related to COVID-19 and acute myocarditis. Additionally, they are developing a subcutaneous formulation of CardiolRx to address fibrosis and inflammation in the heart, key factors in heart failure progression. The company aims to provide novel therapeutic solutions for significant unmet needs in the CVD market.

Is CRDL stock a good buy?

CRDL stock presents a speculative investment opportunity with high potential upside and significant risks. The company's future hinges on the success of its CardiolRx clinical trials. Positive results could lead to substantial gains, while negative results could significantly impact the stock price. With a market cap of $0.10 billion, CRDL offers potential for growth, but investors should carefully consider the inherent risks associated with clinical-stage pharmaceutical companies. The P/E ratio of -3.39 indicates the company is not currently profitable, further emphasizing the speculative nature of the investment. Investors should conduct thorough due diligence and assess their risk tolerance before investing.

What are the main risks for CRDL?

The primary risks for Cardiol Therapeutics revolve around the success of its clinical trials for CardiolRx. Failure to demonstrate efficacy or safety in these trials would significantly impact the company's prospects. Regulatory hurdles and potential delays in obtaining approval for CardiolRx also pose risks. Competition from larger, more established pharmaceutical companies with greater resources is another significant challenge. Additionally, the company's reliance on securing additional funding to support its operations and clinical trials creates financial risk. Changes in healthcare policies and reimbursement rates could also negatively impact the company's future revenue potential.

Is CRDL a good stock to buy?

Whether CRDL is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the CRDL MoonshotScore?

The MoonshotScore for CRDL is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is CRDL data updated?

CRDL stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to CRDL is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for CRDL?

Growth catalysts for Cardiol Therapeutics Inc. (CRDL) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Cardiol Therapeutics Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are CRDL's main competitors?

Cardiol Therapeutics Inc. (CRDL) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether CRDL has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about CRDL?

Wall Street analyst coverage for CRDL includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is CRDL's market cap?

Market capitalization (market cap) for CRDL is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows CRDL's current market cap alongside enterprise value and other valuation metrics.

How has CRDL stock performed recently?

CRDL's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing CRDL's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in CRDL?

Key risk categories for CRDL include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures CRDL's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling CRDL?

Insider trading activity for CRDL tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is CRDL a good stock for beginners?

Cardiol Therapeutics Inc. (CRDL) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is CRDL for first-time investors?

Every stock carries risk, including Cardiol Therapeutics Inc. (CRDL). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like CRDL.